Prescription Predictions & Odds· 137 markets
F
FDA approves Retatrutide this year?
$544k Vol.
$6k Liq.
4
Ends in 9 months
$544k Vol.$6k Liq.4Ends in 9 months
24%
Yes
M
45%
Yes
T
Trump EO implementing “most favored nation” drug pricing by next Friday?
$141k Vol.
$0 Liq.
7
Ended
$141k Vol.$0 Liq.7Ended
Yes
F
Yes
F
FDA approves Leqembi auto-injection for early Alzheimer’s?
$2k Vol.
$0 Liq.
12
Ended
$2k Vol.$0 Liq.12Ended
Yes
F
FDA approves Telix Pharmaceuticals’ TLX250-CDx for kidney cancer imaging?
$3k Vol.
$0 Liq.
12
Ended
$3k Vol.$0 Liq.12Ended
No
F
FDA approves Precigen’s PRGN-2012 for recurrent respiratory papillomatosis?
$15k Vol.
$0 Liq.
12
Ended
$15k Vol.$0 Liq.12Ended
Yes
F
No
F
FDA approves Sanofi’s Rilzabrutinib for immune thrombocytopenia?
$3k Vol.
$0 Liq.
12
Ended
$3k Vol.$0 Liq.12Ended
Yes
F
FDA approves Capricor Therapeutics’ Deramiocel for Duchenne muscular dystrophy by August 31?
$11k Vol.
$0 Liq.
12
Ended
$11k Vol.$0 Liq.12Ended
No
F
FDA approves PTC Therapeutics’ Vatiquinone for Friedreich’s ataxia?
$2k Vol.
$0 Liq.
12
Ended
$2k Vol.$0 Liq.12Ended
No
F
FDA approves Tonix Pharmaceuticals’ TNX-102 SL for fibromyalgia?
$916 Vol.
$0 Liq.
12
Ended
$916 Vol.$0 Liq.12Ended
Yes
F
Yes
F
Yes
F
FDA approves LENZ Therapeutics’ LNZ100 for presbyopia by August 31?
$7k Vol.
$0 Liq.
12
Ended
$7k Vol.$0 Liq.12Ended
Yes